Efficacy of topical latanoprost in the treatment of eyelid vitiligo: A randomized, double-blind clinical trial study

Dermatol Ther. 2020 Jan;33(1):e13175. doi: 10.1111/dth.13175. Epub 2019 Dec 26.


Numerous studies have demonstrated that the pigmentation of iris and around the eyelid is a common side effect of latanoprost, a prostaglandin F2alpha analogue used in the treatment of glaucoma. Hence, the authors decided to study the effectiveness of topical latanoprost on vitiligo patches around the eyelid. In this randomized, double-blind, clinical trial study, 31 patients with vitiligo vulgaris and focal vitiligo involving the eyelids were evaluated. Patients were randomly divided into two groups. First group received topical latanoprost gel twice daily for 12 weeks, whereas the second group received placebo with the same protocol. To evaluate severity of the disease the VIDA rating system was used. Serial photos of the patches were taken to compare and evaluate the repigmentation percentage of the patches. The patients in both groups had almost similar VIDA score (p > .05). First group showed improved pigmentation, whereas participants in the second group did not show any improvement in the pigmentation. The group treated with latanoprost showed significant reduction in the symptoms of the disease, whereas those treated with placebo did not show any alteration (p > .05). No significant complications were observed in either groups. Latanoprost proved effective in treating vitiligo disease involving eyelids.

Keywords: eyelid patch; latanoprost; prostaglandin F2α analogue; vitiligo.

Publication types

  • Randomized Controlled Trial

MeSH terms

  • Administration, Topical
  • Adolescent
  • Child
  • Double-Blind Method
  • Eyelids*
  • Female
  • Gels
  • Humans
  • Latanoprost / administration & dosage*
  • Male
  • Severity of Illness Index
  • Skin Pigmentation / drug effects
  • Treatment Outcome
  • Vitiligo / drug therapy*
  • Vitiligo / pathology
  • Young Adult


  • Gels
  • Latanoprost